The Chugai Group regards global environmental preservation as an important foundation that underpins all of its business activities. To achieve Our Vision by 2030, we have set challenging mid-term environmental goals 2030, based on the global environmental consensus, for the three issues identified as material: climate change countermeasures, use of renewable/recycled resources, and protection of biodiversity, and is actively addressing them.
Mid-Term Environmental Goals 2030 was established with the approval of the Executive Committee and reported of the Board of Directors. The Sustainability Committee thoroughly deliberates the plans and progress of these activities, while the Executive Committee deliberates on important matters and reports them to the Board of Directors.

■Our Vision for Mid-Term Environmental Goals 2030
We consider global environmental protection to be an important foundation for all of our business activities. We have set challenging mid-term environmental goals 2030 based on global environmental consensus, and will strive to be a role model for the world that leads the solution of environmental issues through innovative global environmental conservation activities and active information disclosure based on evidence in cooperation with Roche and external partners.

■Our Strategy for Three Material Issues

• Climate change countermeasures
  Set challenging targets based on international agreements, etc., create and promote new environmental measures through collaboration with suppliers and academia to reduce greenhouse gas emissions and realize efficient use of energy.
• Use of renewable/recycled resources
  In addition to overall waste reduction targets, we have also set targets for reducing plastic waste and water, which are major sources of water pollution. We will make effort to achieve a circular economy by advancing environmentally friendly business activities and jointly developing recycling technologies.
• Protection of Biodiversity
  In addition to our efforts to conserve and restore natural capital, as an R & D-driven pharmaceutical company, we will establish unique reduction targets for hazardous chemical substances and make effort to minimize chemical substance risk throughout the product lifecycle in order to link our precious planet to the next generation.

Environmental Action Goals/Plans

As we work toward achieving our mid-term environmental goals, we have implemented an ongoing program of environmental that involve setting yearly action goals or plans for each item based on the mid-term plan, evaluating the results, and reflecting those results in the following year’s plan.

Environmental Action Goals/Plan and Performance [PDF 603KB]

Industry activities

To promote the reduction of CO₂ emissions as the pharmaceutical industry, we participate in the Environmental Issues Subcommittee of the Japan Pharmaceutical Manufacturers Association (JPMA) and the Carbon Neutral Action Plan Working Group (CN Action Plan Working Group) of the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ). In particular, we participate in the CN Action Plan WG as a leader company, contributing to the promotion of initiatives to reduce CO₂ emissions.

While promoting health and safety activities under the Environment, Health and Safety (EHS management) system in line with our basic approach, we identified and evaluated issues and established six high-priority items in the area of health and productivity management: cancer; lifestyle-related diseases; mental health; health literacy; workplace safety; and organizational climate. We have set medium to long-term goals in each of these areas and are conducting activities to achieve them by 2030, the final year of the goals.

Health management Activity Goals/Plans

To achieve our medium-term health management goals, we set annual goals for each item, evaluate the results of those activities, and reflect those evaluations in activities for the next fiscal year, thereby continuously promoting safety-related activities.

* Measures to Receive Re-Examination for Cancer: Started in 2022 as an initiative to directly approach employees who have been assessed as requiring re-examination in cancer screening. In addition to advising patients to seek medical attention, interview with a nurse with clinical experience in cancer should be held upon request to establish an environment that enables patients to face medical attention positively (2023 investment: ¥4 million/year)

Results of medical checkups and training

Trends in health management target indicators

* In FY 2023, as the choice of absenteeism was changed from “ 0 days ”,“ 1 day ”, ... “ 5 days ” to “ 0 to 5 days ”, it is calculated using the weighted average of the previous year.